Breaking Finance News

Shire PLC (LON:SHP) target bumped down to 5,700.00GBX, issued a ratings update earlier today by Morgan Stanley

Yesterday Shire PLC (LON:SHP) traded 0.12% higher at 3,836.50GBX. SHP’s 50-day average is 3,856.68GBX and its two hundred day average is 4,263.44GBX. The last closing price is down -9.91% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. Trading volume was down over the average, with 302,784 shares of SHP changing hands under the typical 2,742,130

Shire PLC (LON:SHP) had its stock price target reduced to 5,700.00GBX by Morgan Stanley in a report released 10/12/2017. The new target price indicates a potential upside of 0.49% from the company's most recent stock price close.

Previously on Friday August 04, 2017, Deutsche Bank released a statement about Shire PLC (LON:SHP) maintained the target price at 6,000.00GBX. At the time, this indicated a possible upside of 0.42%.

Recent Performance Chart

Shire PLC (LON:SHP)

With a total market value of 0 GBX, Shire PLC has 52 week low of 3,603.50GBX and a 52 week high of 5,218.00GBX with a P/E ratio of 51.56 .

Also covering Shire PLC's target, a total of 18 firms have reported on the stock. The consensus target price is 73.73GBX with six analysts rating the company a strong buy, sixteen brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Shire PLC (LON:SHP)

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *